tbuckley/cabot-search huggingface dataset:
Abstract 3152: A tumor suppressor-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer
Authors: Joshua M. Corbin, Constantin Georgescu, Sandra Thibivilliers, Zachary Webb, Yan Zhao, Jan Koster, Kar-Ming Fung, Adam Asch, Jonathan Wren, Maria Ruiz-Echevarria
Journal: Cancer Research (2019)

Abstract Prostate cancer (PCa) is a complex heterogeneous disease, with the majority of cases remaining indolent and 10% of cases progressing to lethality. While some of this clinical heterogeneity can be explained by traditional clinicopathological factors, molecular profiling studies signal an extraordinary genomic variability, which may lead to diverse clinical outcomes. The identification of molecular subclasses of PCa has the potential to guide the prediction of clinical outcomes, the discovery and design of innovative prognostic biomarkers, and the development of novel therapeutics. To this end, we investigated genes associated with TMEFF2, an androgen-regulated tumor suppressor gene with exceptionally heterogeneous expression in PCa. Low levels of TMEFF2 mRNA significantly (p&amp;lt;0.0001) correlate with reduced disease-free survival (DFS) in patients from the Memorial Sloan Kettering Cancer Center (MSKCC) dataset. Using RNA interference, we identified a panel of 11 TMEFF2 regulated cell cycle related genes (TMCC11), with strong prognostic value. TMCC11 expression stratified radical prostatectomy (RP) patients on the risk of recurrence, served as an independent indicator of poor prognosis, and improved the prognostic value of standard clinicopathological markers in four geographically different patient cohorts (n= 834 samples). The prognostic ability of TMCC11 panel exceeded previously published oncogenic gene signatures (p=0.00017). This study provides evidence that the TMCC11 gene signature is a robust prognostic marker for PCa, reveals the value of using highly heterogeneously expressed genes, like TMEFF2, as guides to discover prognostic indicators, and suggests the possibility that low TMEFF2 expression marks a distinct subclass of PCa. Citation Format: Joshua M. Corbin, Constantin Georgescu, Sandra Thibivilliers, Zachary Webb, Yan Zhao, Jan Koster, Kar-Ming Fung, Adam Asch, Jonathan Wren, Maria Ruiz-Echevarria. A tumor suppressor-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3152.
Abstract 2514: Tetra-O-methyl nordihydroguaiaretic acid (M4N) broadly suppresses cancer metabolism and synergistically induces strong anticancer activity in combination with etoposide, rapamycin and UCN-01
Authors: Kotohiko Kimura, Ru Chih C. Huang
Journal: Cancer Research (2017)

Abstract The ability of Tetra-O-methyl nordihydroguaiaretic acid (M4N) to induce rapid cell death in combination with Etoposide, Rapamycin, or UCN-01 was examined in LNCaP cells, both in cell culture and animal experiments. Mice treated with M4N drug combinations with either Etoposide or Rapamycin showed no evidence of tumor and had a 100% survival rate 100 days after tumor implantation. By comparison all other vehicles or single drug treated mice failed to survive longer than 30 days after implantation. This synergistic improvement of anticancer effect was also confirmed in more than 20 cancer cell lines. In LNCaP cells, M4N was found to reduce cellular ATP content, and suppress NDUFS1 expression while inducing hyperpolarization of mitochondrial membrane potential. M4N-treated cells lacked autophagy with reduced expression of BNIP3 and ATG5. To understand the mechanisms of this anticancer activity of M4N, the effect of this drug on three cancer cell lines (LNCaP, AsPC-1, and L428 cells) was further examined via transcriptome and metabolomics analyses. Metabolomic results showed that there were reductions of 26 metabolites essential for energy generation and/or production of cellular components in common with these three cell lines following 8 hours of M4N treatment. For instance, among the amino acids, the content of aspartate, a key metabolite in electron transport system in the mitochondria, was specifically suppressed by M4N. Deep RNA sequencing analysis demonstrated that there were sixteen genes whose expressions were found to be modulated following 6 hours of M4N treatment similarly in these three cell lines. Six out of these 16 genes were functionally related to the 26 metabolites described above. One of these up-regulated genes encodes for CHAC1, a key enzyme affecting the stress pathways through its degradation of glutathione. In fact M4N was found to suppress glutathione content and induce reactive oxygen species production. The data overall indicate that M4N has profound specific negative impacts on a wide range of cancer metabolisms supporting the use of M4N combination for cancer treatments. Citation Format: Kotohiko Kimura, Ru Chih C. Huang. Tetra-O-methyl nordihydroguaiaretic acid (M4N) broadly suppresses cancer metabolism and synergistically induces strong anticancer activity in combination with etoposide, rapamycin and UCN-01 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2514. doi:10.1158/1538-7445.AM2017-2514
A population-based analysis of urban-rural disparities in advanced pancreatic cancer (APC) management and outcomes.
Authors: Thomas Canale, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2017)

e18049 Background: The high morbidity burden associated with APC means that its management is complex and frequently requires multidisciplinary care. Because of potential geographical barriers to healthcare access, we aimed to determine the effect of rurality on management and outcomes of APC patients. Methods: Patients diagnosed with APC (locally advanced or metastatic disease) from 2008 to 2015 and received gemcitabine (gem), gem plus nabpaclitaxel (gem/nab), or FOLFIRINOX at any 1 of 6 British Columbia cancer centers were reviewed. Using postal codes, the Google Maps Distance Matrix determined the distance from each patient’s residence to the closest cancer center. Rural and urban status were defined as patients living &gt; / = 100 km and &lt; 100 km to the closest treatment site, respectively. Different cut points were used in sensitivity analyses. Patients were also stratified according to Canadian census population sizes. Univariate and Cox regression analyses were applied to examine whether rurality resulted in variations in management and outcomes. Results: In total, we identified 659 patients: median age 68 years, 54.3% men, and 45.7% metastatic disease. Among them, 19.3% lived rurally. For treatment, 67.7%, 9.2%, and 23.1% received gem, gem/nab, and FOLFIRINOX, respectively. There were no differences in baseline clinical characteristics between rural and urban patients (all p &gt; 0.05). Time from diagnosis to oncology appointment and time from appointment to treatment were 31.5 and 29.5 days for rural patients and 28.6 and 40.1 days for urban patients, respectively (all p &gt; 0.05). In multivariate Cox regression, risk of death was similar between rural and urban groups (HR 0.864, 95% CI 0.619-1.206, p = 0.390). Furthermore, regression analysis found that population size did not pose a signficiant impact on APC outcomes (all p &gt; 0.05). Conclusions: There was no correlation between rurality and outcomes in APC. The strategic and geographic allocation of cancer care delivery across 6 comprehensive treatment centers in British Columbia may serve as a model for other jurisdictions, particularly those that currently face outcome disparities in cancers that often require complex multidisciplinary care
Herpetic Tracheobronchitis
Authors: M K Sherry, A S Klainer, M Wolff, H Gerhard
Journal: Annals of Internal Medicine (1988)

Nine adult patients from three community teaching hospitals had bronchospasm unresponsive to standard therapy. Bronchoscope, cytologic, histopathologic, and virologic studies confirmed that necrotizing and exudative tracheobronchitis was due to herpes simplex virus. No patient had a history of previous chronic lung disease; most were not immunocompromised. Three patients never had intubation during hospitalization. All patients were successfully treated with intravenous acyclovir. Herpetic tracheobronchitis may be a commoner clinical syndrome than generally assumed. In an elderly patient with unresolving acute bronchospasm, herpesvirus infection of the lower respiratory tract should be considered in the differential diagnosis. In the immunocompetent host, antiviral therapy can successfully treat herpesvirus respiratory infection, with reversal of clinical, virologic, and pathologic findings. A prompt and accurate diagnosis is crucial.
The krebiozen story. Is cancer quackery dead?
Authors: J. F. Holland
Journal: JAMA (1967)

My definition of cancer quackery is the<i>deliberate</i>misapplication of a diagnostic or treatment procedure in a patient with cancer. Those who misapply diagnostic or treatment methods<i>unknowingly</i>may be honestly mistaken, inept, or fools. But the culprit who victimizes his fellowman suffering from cancer, impeding the patient's access to available therapies or constructive investigation, all the while greedily enriching himself, is a quack, a criminal, a jackal among men who deserves the scorn and ostracism of society. Because human life is at stake, he must be controlled. The Commissioner of the US Food and Drug Administration has described krebiozen as a "cruel hoax." He has stated, "Each day a person with treatable cancer relies upon krebiozen is a day that brings him closer to death." This unambiguous stand leads us to review the background of the krebiozen tragedy, to determine how krebiozen reached its pinnacle of notoriety and why
FRI0053 IL-21 induces socs-mediated suppression of TLR triggering but aggravates TH17-driven destructive arthritis
Authors: M.I. Koenders, S. Abdollahi-Roodsaz, R. Marijnissen, D. Young, C. Nickerson-Nutter, F. van de Loo, A. Boots, W. van den Berg
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> IL-21 is an immune-regulatory cytokine that can have both proinflammatory and immunosuppressive effects. <h3>Objectives</h3> The purpose of this study was to investigate the potential dual role of IL-21 in experimental arthritis. <h3>Methods</h3> For <i>in vitro</i> studies, freshly isolated C57Bl6 splenocytes were stimulated with TLR2/NOD2-binding ligands in the presence or absence of IL-21. In addition, chronic Streptococcal Cell Wall (SCW) arthritis and antigen-induced arthritis (AIA) were induced in IL-21-receptor-deficient (IL-21R-/-) mice and wild-type (WT) controls. <h3>Results</h3> <i>In vitro</i> stimulation of splenocytes with TLR2/NOD2-binding SCW fragments resulted in enhanced production of IL-6 and CXCL1, but not IL-10. Interestingly, this proinflammatory response was blocked in the presence of IL-21. QPCR analysis demonstrated that IL-21 strongly induced SOCS expression, suggesting a SOCS-dependent immunosuppressive effect of IL-21 on TLR signaling. In contrast, at first sight our <i>in vivo</i> studies using IL-21R-deficient mice showed a proinflammatory role of IL-21 in experimental arthritis. In both SCW-induced arthritis and AIA, IL-21R-deficiency protected against severe joint inflammation and destruction. This reduced pathology in IL-21R-/- mice was accompanied by suppressed antigen-specific T cell responses, decreased serum IgG1 levels, reduced IL-17 levels in joint lavage, and lower numbers of IL-17+ IFNγ+ T cells in the joint. However, during every local (re)challenge of SCW arthritis with TLR ligands, a clearly enhanced joint swelling was found in IL-21R-deficient mice. No differences were found in the expression of TLR2 and NOD2, the most important receptors for SCW. However, while the WT showed a massive upregulation of SOCS1/3 at day 4 of arthritis, IL-21R-/- mice were significantly less capable in upregulating these genes. These data suggest that impaired SOCS regulation in the absence of IL-21 signaling contributes to the increased local activation during SCW arthritis. <h3>Conclusions</h3> In contrast to the proinflammatory role of IL-21 in adaptive immunity, driving IL-17/IFNγ double-positive cells and joint pathology during chronic experimental arthritis, IL-21 has an important immunosuppressive role in innate immunity by inhibiting TLR signaling via SOCS1/3. If this dual role of IL-21 in various immune processes is present in human disease, it could make IL-21 a difficult therapeutic target in RA that requires cell-specific targeting during RA. <h3>Disclosure of Interest</h3> None Declared
Low dietary intake of linoleic acid predisposes to myocardial infarction
Authors: H C R Simpson, K Barker, R D Carter, E Cassels, J I Mann
Journal: BMJ (1982)

Thirty-two men who had recently had a myocardial infarction were matched individually for age with controls who had no evidence of heart disease. The patients had a significantly lower proportion of linoleic acid and a higher proportion of palmitic acid in their plasma triglyceride fatty acids. Analysis of the composition of red-cell membrane phosphatidyl choline, which reflects long-term dietary fat intake, showed a significantly lower proportion of linoleic acid in the patients. These differences suggest that the type of dietary fat consumed might be an important factor in the genesis of ischaemic heart disease.
JAMA Psychiatry
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Kevin Brown, Amanda Ehrhardt, Iris Lo, M Newman, Suzanne Walker, Connie Manno, Sara Billings, Timothy Gray, Paul Ruich, Sam Wilder, Catherine Alden, Stephanie Beckmeyer, Jane Calayag, Jan Clavey, Mary Coerver-Connolly, Paula Glitman, Laura King, Joseph Mills, Brandy Patton, Donna Thordsen, Editorial Assistant, Wanda Hill, Larry Bryant, Monica Mungle, Elaine Williams, Fanny Brown, Anna Bukowski, Lenette Gardner-Gullens, Tosca Hall, Erin Kato, Peter Kim, Rachell Lozano, Caroline Sietmann, Angelia Waltower, Michael Berkwits, Eric Butkus, Michelle Kurzynski, Emily Ling, Jesse Mcquarters, Daniel Morrow, Daniella Peting, Reuben Rios, Carrie Butt, Mary Ferkaluk, Ronna Henry, Karen Bucher, Andy Rekito, Nick Reback, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Marketing Thornbury, Tricia Classifi, Thalia Moss, Tiff Stevenson, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, David Baum, Morgan Osgood, Ron Marketing, Rick Bell, Elizabeth Solaro, Sara Zimmerman, Geoff Rey, Fergus Clare, Lindsay Dawson, Will English, Ellen Gibson, Mustafa Ishaq, Peter Litton, Craig Mccaff Rey, Michael Mcgraw, Jon Perkins, Daniel Pickhardt, Romando Rossini, Sarah Subramanian, Stacy Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Tom Miller, Karl Elvin, Nancy Essex, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Jennifer Carney, Lydia Cruz, Scott Curl, Diane Darnell, Jordynn Farrar, Colleen Kelly, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Binita Shah, Erin Spencer, Denise Steinhauser, Joe Advertising, Production Services, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Michael Deegan, Daniel Degroot, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Joshua Lampinen, Nathan Mitre, Patricia Panek, Marla Seidell, La Son Diggs, Joe Amft, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Bernard Hengesbaugh, Constance Murphy, Martin Paulus, Christine Konradi, Helena Chmura Kraemer, Palo Alto, Howard Bauchner
Journal: JAMA Psychiatry (2018)
PROTEIN AND CARBOHYDRATE EQUIVALENTS IN THE DIABETIC DIETARY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Open-Heart Surgery and The Psyche
Authors: Harry S. Abram
Journal: JAMA (1970)

<h3>To the Editor.—</h3> Your editorial "Open-Heart Surgery and the Psyche" (<b>212</b>:1370, 1970) is so dogmatic and final! Need there be a "victor?" I think the comments are oversimplistic and show a naivety of the mind-body problem which is frankly rather frightening. If you really read my work, as well as that of others (such as Kornfeld et al),<sup>1</sup>you will find no assertion that all the psychiatric complications following open-heart operations are "functional" in nature. For we are all aware there are a<i>multiplicity</i>of factors involved in the patient's response to cardiac operations. Indeed I mention Gilman's article<sup>2</sup>in my original paper,<sup>3</sup>and in other writings note "multiple etiologies" involved in postoperative reactions. At a time when psychiatry is moving toward medicine and psychiatrists are collaborating with their medical and surgical colleagues to understand the<i>complexity</i>involved in patients' responses to physical illnesses and operative
Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction
Authors: Koji Sasaki, Hagop M Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Sherry Pierce, Gautam Borthakur, Tapan M. Kadia, Naveen Pemmaraju, Alessandra Ferrajoli, Susan O'Brien, Jorge E. Cortes
Journal: Blood (2013)
Withdrawn
Authors: Whitney Stevens, Anna Staudacher, Kathryn Hulse, Roderick Carter, Deborah Winter, Atsushi Kato, Ly- Dia Suh, James Norton, Julia Huang, Anju Peters, Msci Faaaai, Leslie Grammer, David Conley, Stepha- Nie Shintani, Bruce Tan, Kevin Welch, Robert Kern, Robert Schleimer
Journal: Journal of Allergy and Clinical Immunology (2020)
The epidemiology and natural history of pressure ulcers in elderly nursing home residents
Authors: G. H. Brandeis
Journal: JAMA (1990)

We analyzed prospective data from 19 889 elderly residents of 51 nursing homes from 1984 to 1985 to determine the prevalence, incidence, and natural history of pressure ulcers. Among all residents admitted to nursing homes, 11.3% possessed a stage II through stage IV pressure ulcer. For those residents admitted to the nursing home without pressure ulcers during the study period, the 1-year incidence was 13.2%. This increased to 21.6% by 2 years of nursing home stay. People already residing in a nursing home at the start of the study had a 1-year incidence of 9.5%, which increased to 20.4% by 2 years. Pressure ulcers were associated with an increased rate of mortality, but not hospitalization. Longitudinal follow-up of residents with pressure ulcers demonstrated that a majority of their lesions were healed by 1 year. Most of the improvement occurred early in a person's nursing home stay. Although nursing home residents with pressure ulcers have a higher mortality, with good medical care pressure ulcers can be expected to heal. (<i>JAMA</i>. 1990;264:2905-2909)
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling
Authors: Andreas Sturm, Jugoh Itoh, James W. Jacobberger, Claudio Fiocchi
Journal: Journal of Clinical Investigation (2002)

To mount an effective immune response, T cells must divide in response to antigen contact. To maintain tolerance, mucosal lamina propria T cells (LPTs) may adapt their cycling to an antigen-rich gut stimulatory environment. Here, we compared the cell cycle kinetics of LPTs and peripheral blood T cells (PBTs) before and after CD3- and CD2-mediated activation. While CD3-activated naive (CD45RA+) and memory (CD45RO+) PBTs peaked in the S and G2/M phase at 2–3 days, CD3-activated LPTs peaked at 4–6 days. In contrast, CD2 activation induced modest PBT but vigorous LPT cycling. The doubling time of CD3-activated PBTs was 1 day, while that of CD3- or CD2-activated LPTs was 2 days. LPTs failed to upregulate cyclin-dependent kinase 4 and cyclin D3, but Rb phosphorylation and cyclin A and B1 upregulation were induced by CD2 engagement. The extents of clonal expansion in LPT and PBT were comparable, indicating that LPTs' slow replication delays but does not hinder cell division. CD2-activated LPTs displayed a striking upregulation of p53, whose blockade by antisense oligonucleotides accelerated their S phase transit time to that of CD3-activated PBTs. By slowing LPT cycling, p53 may act as a negative regulator of mucosal immunity, promoting immunological tolerance by preventing excessive T cell replication.
Scintilla
Authors: Clayton J. Baker
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal